Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 02, 2007. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding changes in beneficial interests in the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of a specific share transaction rather than a financial performance report.
Material Changes
The only material change disclosed is a transaction involving Mr. R Bondy, who acquired a beneficial interest in 1 Ordinary Share. The share was purchased under a Personal Equity Plan on October 1, 2007, at a price of GBP 13.09 per share.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risks, contingencies, or unusual items. It strictly adheres to the Disclosure and Transparency Rule 3.1.4R(1)(a) regarding the notification of the aforementioned transaction.
Key Facts for Investor Verification
- Transaction Date: October 1, 2007.
- Individual: Mr. R Bondy.
- Instrument: 1 Ordinary Share acquired via Personal Equity Plan.
- Price: GBP 13.09 per share.
- Notification Date: October 2, 2007.